Transcatheter Complete Heart Assist Device
Features
The transcatheter complete heart assist device consists of a stent-membrane assembly that can be activated in order to reproduce a pulsatile flow in heart cavities, including both systolic and diastolic phases. The cyclic deformation of the membrane can be adjusted for heart rate and stroke volume depending on patient needs.
Advantages
- Minimally invasive surgery
- Support for left, right or both ventricles
- Adjustable pulsatile flow
- Possibility to change the membrane using a stent-in-stent approach in case of failure
- Original design minimizing hemolysis
- Scalable design for young or elderly patient
- For patients with severe CHF as a bridge to transplantation or a destination therapy
Current Status
- A first prototype of left ventricular assist device (LVAD) was designed and successfully tested in a heart simulator and a bi-ventricular assist device (Bi-VAD) prototype is also in development for severe CHF.
Opportunities
Market opportunities:
- (CVDs) are the first cause of (31% of all death)
- Congestive heart failure (CHF) is a the pumping power of the heart
- 7 million patients with CHF in US with 550,000 new cases each year and mortality up to 50% within 5 years
- Severe CHF but the number of donors is low, leading to long waiting period
- Lifesaving option is the use of engineered heart assist devices for
Patents opportunities: US Provisional patent
Business opportunities: partnering/licensing